e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serotonergic antidepressants in COPD: beneficial or harmful?
Abebaw Mengistu Yohannes
Source:
Eur Respir J, 52 (1) 1801095; 10.1183/13993003.01095-2018
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Abebaw Mengistu Yohannes. Serotonergic antidepressants in COPD: beneficial or harmful?. Eur Respir J, 52 (1) 1801095; 10.1183/13993003.01095-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Are bronchodilator drugs really useful in COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 94s
Year: 2001
Detrimental effects of Beta-blockers in COPD
Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD
Year: 2009
Serotonergic antidepressant use and morbidity and mortality among older adults with COPD
Source: Eur Respir J, 52 (1) 1800475; 10.1183/13993003.00475-2018
Year: 2018
Efficacy of antiepileptic drugs diphenine and carbamazepine in pharmacotherapy of children with bronchial asthma: is asthma a neurogenic inflammatory disease?
Source: Eur Respir J 2006; 28: Suppl. 50, 204s
Year: 2006
Reducing cholinergic constriction: the major reversible mechanism in COPD
Source: Eur Respir Rev 2006; 15: 32-36
Year: 2006
Opioid use, perhaps a harbinger of worsening COPD?
Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases
Year: 2020
Is the coprescription of Beta-blockers and Beta2-agonists justified in patients with coexisting COPD and CHF?
Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD
Year: 2009
T-cells in COPD: harmful or protective?
Source: Annual Congress 2012 - ERS COPD Research Award Ceremony (supported by Boehringer Ingelheim) followed by the Hot Topic "It takes two to tango: innate and adaptive immunity in COPD"
Year: 2012
Pharmacological actions of statins: potential utility in COPD
Source: Eur Respir Rev 2009; 18: 222-232
Year: 2009
Efficacy of monotherapy with anticonvulsive drugs topiramate and carbamazepine in bronchial asthma: is asthma a neurological disease?
Source: Eur Respir J 2004; 24: Suppl. 48, 130s
Year: 2004
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Source: Eur Respir Rev 2015; 25: 54-64
Year: 2016
Is it safe to prescribe benzodiazepines or opioids for dyspnoea in interstitial lung disease?
Source: Breathe, 15 (2) 137; 10.1183/20734735.0015-2019
Year: 2019
Targeting neuropetides: from antiemetics to bronchodilators?
Source: Annual Congress 2012 - ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline) followed by the Hot Topic "The nerves are back!"
Year: 2012
Targeting the detrimental effects of sleep disturbances in OSA: CPAP and what else?
Source: Research seminar - Targeting the detrimental effects of sleep disturbances and disorders – towards personalized treatment in respiratory diseases
Year: 2019
Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma?
Source: Eur Respir J 2001; 17: 1059-1061
Year: 2001
Adverse respiratory effects of opioids for chronic breathlessness: to what extent can we learn lessons from chronic pain?
Source: Eur Respir J, 52 (1) 1800882; 10.1183/13993003.00882-2018
Year: 2018
Initial anticholinergic therapy COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 29s
Year: 2006
Next generation of anti-inflammatory therapy for COPD?
Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept